News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cancer Vaccine Maker Dendreon Corporation (DNDN) Can't Meet Demand



6/28/2010 8:22:45 AM

Portfolio.com -- Dendreon Corp. raised more than $400 million in a secondary offering last December to build factories so it could produce enough of its prostate cancer vaccine. At the time, the product wasn't even approved. Now that the vaccine Provenge is being sold, the company can't keep up with demand.

Read at News Release
Read at Business Week


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES